Economic effects of aspergillosis management in high-risk patients.
Aspergillosis mortality has risen exponentially over the last 2 decades, related primarily to the availability of medical treatments and procedures that prolong the survival of patients with other disorders who are at high risk because of immunologic compromise. In addition to excess mortality, aspergillosis results in increased costs for hospitalization and treatment, including management of adverse events associated with conventional amphotericin B treatment. Compared with amphotericin B, the triazole antifungal voriconazole has excellent efficacy and a favorable side-effect profile. Reliable oral bioavailability of voriconazole may permit switching to an oral formulation in the inpatient setting and offers the possibility of earlier hospital discharge and potentially substantial cost savings.
Leather
Helen
H
BMT/Leukemia, Shands at the University of Florida, Gainesville, 32610-0316, USA.
D000666:Amphotericin B / Q000191:economics / Q000627:therapeutic use; D000935:Antifungal Agents / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D007349:Insurance, Health, Reimbursement; D011743:Pyrimidines / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D014230:Triazoles / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D014481:United States; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D065819:Voriconazole